Cidara Historical Financial Ratios

CDTX Stock

USD 22.39 0.81 3.75%

Cidara Therapeutics is presently reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.1 or Days Sales Outstanding of 509 will help investors to properly organize and evaluate Cidara Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

About Cidara Financial Ratios Analysis

Cidara TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cidara Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cidara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cidara Therapeutics history.

Cidara Therapeutics Financial Ratios Chart

At this time, Cidara Therapeutics' Capex To Revenue is fairly stable compared to the past year. EV To Operating Cash Flow is likely to rise to 0.09 in 2025, whereas Book Value Per Share is likely to drop 24.43 in 2025.

Price To Sales Ratio Days Sales Outstanding Payables Turnover Capex To Revenue

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cidara Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cidara Therapeutics sales, a figure that is much harder to manipulate than other Cidara Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most ratios from Cidara Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Capex To Revenue is fairly stable compared to the past year. EV To Operating Cash Flow is likely to rise to 0.09 in 2025, whereas Book Value Per Share is likely to drop 24.43 in 2025.

	2022	2023	2024	2025 (projected)
Interest Debt Per Share	0.43	1.12	0.56	0.54
Revenue Per Share	18.41	14.62	0.2	0.19

Interest Debt Per Share Revenue Per Share

Cidara Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.19	0.88	-0.08	-0.73	0.16	-0.28	0.19	-0.96	0.15	0.0	0.31	0.15	0.37	0.73	0.75	0.99	-0.13	0.41	0.11	0.29	0.41	-0.57	0.1	-0.22	0.34
Ptb Ratio	0.19		0.29	0.25	-0.42	0.16	-0.65	1.0	-0.21	0.13	-0.57	-0.03	-0.1	-0.14	0.32	0.2	0.22	0.3	0.36	-0.13	0.7	0.38	-0.41	0.03	-0.91	0.72
Days Sales Outstanding	0.88	0.29		-0.16	-0.75	0.29	-0.35	0.29	-0.84	0.28	-0.15	0.45	0.23	0.05	0.77	0.73	0.92	-0.22	0.52	0.15	0.42	0.52	-0.7	0.09	-0.38	0.42
Book Value Per Share	-0.08	0.25	-0.16		-0.14	-0.79	0.15	0.25	0.13	-0.82	0.01	-0.06	-0.88	0.07	-0.15	-0.15	-0.1	0.98	0.08	-0.03	-0.18	0.11	0.12	-0.26	-0.24	0.42
Free Cash Flow Yield	-0.73	-0.42	-0.75	-0.14		-0.02	0.47	-0.42	0.7	0.0	0.13	-0.1	0.06	-0.13	-0.54	-0.53	-0.74	-0.06	-0.82	-0.06	-0.47	-0.83	0.45	-0.2	0.42	-0.75
Operating Cash Flow Per Share	0.16	0.16	0.29	-0.79	-0.02		-0.57	0.16	-0.27	1.0	-0.32	0.11	0.96	-0.12	0.3	0.32	0.2	-0.8	0.02	0.07	0.66	0.01	-0.29	0.32	-0.08	0.0
Capex To Depreciation	-0.28	-0.65	-0.35	0.15	0.47	-0.57		-0.65	0.33	-0.55	0.16	0.1	-0.42	0.23	-0.45	-0.11	-0.3	0.18	-0.45	0.19	-0.95	-0.46	0.4	-0.14	0.57	-0.66
Pb Ratio	0.19	1.0	0.29	0.25	-0.42	0.16	-0.65		-0.21	0.13	-0.57	-0.03	-0.1	-0.14	0.32	0.2	0.22	0.3	0.36	-0.13	0.7	0.38	-0.41	0.03	-0.91	0.72
Ev To Sales	-0.96	-0.21	-0.84	0.13	0.7	-0.27	0.33	-0.21		-0.26	0.12	-0.4	-0.23	-0.37	-0.65	-0.82	-0.96	0.18	-0.45	-0.14	-0.36	-0.45	0.46	-0.17	0.16	-0.4
Free Cash Flow Per Share	0.15	0.13	0.28	-0.82	0.0	1.0	-0.55	0.13	-0.26		-0.28	0.1	0.97	-0.11	0.29	0.3	0.19	-0.82	0.0	0.06	0.64	-0.02	-0.28	0.32	-0.06	-0.04
Roic	0.0	-0.57	-0.15	0.01	0.13	-0.32	0.16	-0.57	0.12	-0.28		-0.2	-0.13	-0.15	-0.04	-0.55	-0.06	-0.01	-0.23	-0.01	-0.44	-0.24	0.31	-0.33	0.42	-0.41
Inventory Turnover	0.31	-0.03	0.45	-0.06	-0.1	0.11	0.1	-0.03	-0.4	0.1	-0.2		0.09	-0.13	-0.04	0.42	0.36	-0.07	0.11	0.0	-0.01	0.12	0.04	0.03	0.08	0.07
Net Income Per Share	0.15	-0.1	0.23	-0.88	0.06	0.96	-0.42	-0.1	-0.23	0.97	-0.13	0.09		-0.06	0.23	0.26	0.18	-0.9	-0.08	0.05	0.49	-0.1	-0.22	0.34	0.13	-0.2
Days Of Inventory On Hand	0.37	-0.14	0.05	0.07	-0.13	-0.12	0.23	-0.14	-0.37	-0.11	-0.15	-0.13	-0.06		0.11	0.49	0.33	0.07	-0.07	-0.03	-0.14	-0.06	-0.07	0.47	0.33	-0.09
Payables Turnover	0.73	0.32	0.77	-0.15	-0.54	0.3	-0.45	0.32	-0.65	0.29	-0.04	-0.04	0.23	0.11		0.51	0.75	-0.2	0.37	0.15	0.45	0.37	-0.83	-0.09	-0.41	0.33
Average Inventory	0.75	0.2	0.73	-0.15	-0.53	0.32	-0.11	0.2	-0.82	0.3	-0.55	0.42	0.26	0.49	0.51		0.79	-0.2	0.36	0.14	0.32	0.37	-0.58	0.32	-0.16	0.33
Capex To Revenue	0.99	0.22	0.92	-0.1	-0.74	0.2	-0.3	0.22	-0.96	0.19	-0.06	0.36	0.18	0.33	0.75	0.79		-0.16	0.44	0.12	0.33	0.45	-0.61	0.11	-0.25	0.37
Cash Per Share	-0.13	0.3	-0.22	0.98	-0.06	-0.8	0.18	0.3	0.18	-0.82	-0.01	-0.07	-0.9	0.07	-0.2	-0.2	-0.16		-0.02	-0.05	-0.21	0.01	0.17	-0.27	-0.28	0.35
Pocfratio	0.41	0.36	0.52	0.08	-0.82	0.02	-0.45	0.36	-0.45	0.0	-0.23	0.11	-0.08	-0.07	0.37	0.36	0.44	-0.02		-0.1	0.46	1.0	-0.37	0.16	-0.34	0.8
Interest Coverage	0.11	-0.13	0.15	-0.03	-0.06	0.07	0.19	-0.13	-0.14	0.06	-0.01	0.0	0.05	-0.03	0.15	0.14	0.12	-0.05	-0.1		-0.16	-0.1	0.05	-0.17	0.13	-0.1
Capex To Operating Cash Flow	0.29	0.7	0.42	-0.18	-0.47	0.66	-0.95	0.7	-0.36	0.64	-0.44	-0.01	0.49	-0.14	0.45	0.32	0.33	-0.21	0.46	-0.16		0.47	-0.51	0.27	-0.6	0.68
Pfcf Ratio	0.41	0.38	0.52	0.11	-0.83	0.01	-0.46	0.38	-0.45	-0.02	-0.24	0.12	-0.1	-0.06	0.37	0.37	0.45	0.01	1.0	-0.1	0.47		-0.37	0.16	-0.35	0.82
Days Payables Outstanding	-0.57	-0.41	-0.7	0.12	0.45	-0.29	0.4	-0.41	0.46	-0.28	0.31	0.04	-0.22	-0.07	-0.83	-0.58	-0.61	0.17	-0.37	0.05	-0.51	-0.37		-0.03	0.59	-0.36
Income Quality	0.1	0.03	0.09	-0.26	-0.2	0.32	-0.14	0.03	-0.17	0.32	-0.33	0.03	0.34	0.47	-0.09	0.32	0.11	-0.27	0.16	-0.17	0.27	0.16	-0.03		0.14	0.08
Roe	-0.22	-0.91	-0.38	-0.24	0.42	-0.08	0.57	-0.91	0.16	-0.06	0.42	0.08	0.13	0.33	-0.41	-0.16	-0.25	-0.28	-0.34	0.13	-0.6	-0.35	0.59	0.14		-0.63
Ev To Operating Cash Flow	0.34	0.72	0.42	0.42	-0.75	0.0	-0.66	0.72	-0.4	-0.04	-0.41	0.07	-0.2	-0.09	0.33	0.33	0.37	0.35	0.8	-0.1	0.68	0.82	-0.36	0.08	-0.63

Click cells to compare fundamentals

Cidara Therapeutics Account Relationship Matchups

Cidara Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	6.89	1.34	0.82	1.09	133.87	140.56
Ptb Ratio	7.76	3.09	(18.2)	(8.46)	1.05	1.1
Days Sales Outstanding	338.02	39.44	33.12	92.79	484.95	509.2
Book Value Per Share	5.16	8.23	(0.83)	(1.88)	25.72	24.43
Operating Cash Flow Per Share	(26.19)	(9.63)	(8.15)	(5.13)	(27.8)	(29.19)
Stock Based Compensation To Revenue	0.34	0.081	0.0549	0.0479	3.06	3.22
Capex To Depreciation	0.0933	0.81	(0.0333)	0.0963	4.28	0.53
Pb Ratio	7.76	3.09	(18.2)	(8.46)	1.05	1.1
Ev To Sales	4.57	0.19	0.33	0.6	(12.21)	(11.6)
Free Cash Flow Per Share	(26.28)	(9.64)	(8.19)	(5.25)	(27.82)	(29.21)
Roic	(2.34)	(0.95)	(1.59)	(27.37)	(1.06)	(1.11)
Net Income Per Share	(34.83)	(16.75)	(8.53)	(5.25)	(26.75)	(28.08)
Research And Ddevelopement To Revenue	5.64	1.47	1.17	1.07	56.38	59.19
Capex To Revenue	0.0154	8.27E-4	0.001835	0.007902	0.1	0.11
Cash Per Share	17.28	23.76	9.37	8.18	29.9	28.4
Pocfratio	(1.53)	(2.64)	(1.86)	(3.09)	(0.97)	(1.02)
Interest Coverage	(188.8)	(274.23)	(199.32)	(155.59)	(140.03)	(147.03)
Capex To Operating Cash Flow	(0.003418)	(0.001625)	(0.004144)	(0.0225)	(7.31E-4)	(7.67E-4)
Pfcf Ratio	(1.52)	(2.63)	(1.85)	(3.03)	(0.97)	(1.01)
Days Payables Outstanding	24.51	2.5K	3.7K	903.99	15.51	14.74
Income Quality	0.69	0.75	0.59	0.98	1.04	0.66
Roe	(6.75)	(2.04)	10.26	2.79	(1.04)	(0.99)
Ev To Operating Cash Flow	(1.01)	(0.37)	(0.75)	(1.72)	0.0882	0.0926
Pe Ratio	(1.15)	(1.52)	(1.77)	(3.03)	(1.01)	(1.06)
Ev To Free Cash Flow	(1.01)	(0.37)	(0.75)	(1.68)	0.0881	0.0925
Earnings Yield	(0.87)	(0.66)	(0.56)	(0.33)	(1.0)	(1.04)
Net Debt To E B I T D A	0.39	1.35	0.94	1.27	1.06	1.36
Current Ratio	1.48	2.11	1.5	0.9	4.25	5.21
Tangible Book Value Per Share	5.16	8.23	(0.83)	(1.88)	25.72	24.43
Receivables Turnover	1.08	9.26	11.02	3.93	0.75	0.72
Shareholders Equity Per Share	5.16	8.23	(0.83)	(1.88)	25.72	24.43
Debt To Equity	0.74	0.23	(0.45)	(0.59)	0.0219	0.023
Capex Per Share	0.0895	0.0156	0.0338	0.12	0.0203	0.0193
Graham Net Net	(2.61)	4.29	(3.83)	(5.54)	21.99	20.89

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Cidara Historical Financial Ratios

About Cidara Financial Ratios Analysis

Cidara Therapeutics Financial Ratios Chart

Price To Sales Ratio

Payables Turnover

Capex To Revenue

Cidara Therapeutics fundamentals Correlations

Cidara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cidara Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Cidara Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Capex To Revenue	+ 0.99	Price To Sales Ratio
Cash Per Share	+ 0.98	Book Value Per Share
Net Income Per Share	+ 0.97	Free Cash Flow Per Share

Capex To Revenue	- 0.96	Ev To Sales
Ev To Sales	- 0.96	Price To Sales Ratio
Capex To Operating Cash Flow	- 0.95	Capex To Depreciation
Roe	- 0.91	Pb Ratio
Roe	- 0.91	Ptb Ratio
Cash Per Share	- 0.9	Net Income Per Share